TrialNeurology2014
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.
Volker Limmroth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this papertrialcites it
TrialNeurology2014
Volker Limmroth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.